Skip to main
HOTH
HOTH logo

Hoth Therapeutics (HOTH) Stock Forecast & Price Target

Hoth Therapeutics (HOTH) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Hoth Therapeutics Inc. is effectively pursuing a dual-track strategy in both supportive oncology and metabolic diseases, which enhances its potential for incremental value generation through the advancement of joint venture programs. Clinical data indicating that over 65% of participants experienced reductions in pain and pruritus from their treatments highlights significant therapeutic efficacy and supports the viability of its lead asset, HT-001. Additionally, the company's second quarter 2025 results demonstrate disciplined expense management while progressing the development of HT-001, reinforcing a foundational financial discipline that bodes well for future growth.

Bears say

Hoth Therapeutics Inc. reported zero revenues for the second quarter of 2025, which continues to raise concerns regarding the company's revenue generation capabilities. Total operating expenses were $2.2 million, a decrease from $3.4 million in the previous quarter, yet the firm still incurred a net loss of $2.2 million, translating to a loss of $(0.17) per share. The absence of revenue coupled with ongoing losses highlights the financial challenges Hoth faces as it advances its clinical-stage candidates.

Hoth Therapeutics (HOTH) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Hoth Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Hoth Therapeutics (HOTH) Forecast

Analysts have given Hoth Therapeutics (HOTH) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Hoth Therapeutics (HOTH) has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Hoth Therapeutics (HOTH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.